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Abstract
Monocytes/macrophages displaying different markers of activation/differentiation infiltrate the inflamed gut of patients
with inflammatory bowel diseases (IBD), but the role that each monocyte/macrophage subpopulation plays in the
pathogenesis of IBD is not fully understood. The hemoglobin scavenger receptor CD163, a specific marker of monocytes/
macrophages, has been associated with either anti-inflammatory or inflammatory functions of macrophages in several
pathologies. In this study we examined the tissue distribution and function of CD163-expressing monocytes/macrophages
in IBD. CD163 RNA and protein expression was more pronounced in IBD in comparison to normal controls, with no
significant difference between Crohn’s disease and Ulcerative colitis. In IBD, over-expression of CD163 was restricted to
areas with active inflammation and not influenced by current therapy. Immunohistochemical analysis confirmed the
accumulation of CD163-expressing cells in IBD, mostly around and inside blood vessels, thus suggesting that these cells are
partly recruited from the systemic circulation. Indeed, FACS analysis of circulating mononuclear cells showed that the
fractions of CD163-positive monocytes were increased in IBD patients as compared to controls. Functionally, interleukin-6
up-regulated CD163 expression in lamina propria mononuclear cells and mucosal explants of normal subjects. In IBD blood
and mucosal cell cultures, cross-linking of CD163 with a specific monoclonal anti-CD163 antibody enhanced tumor necrosis
factor-a synthesis. These findings indicate that IBD mucosa is abundantly infiltrated with CD163-positive cells, which could
contribute to amplify the inflammatory cytokine response.
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Introduction
The gastrointestinal mucosa is the largest body surface to
interface with the external environment and the largest reservoir of
macrophages in the body [1,2]. Preferentially located in the
subepithelial lamina propria, intestinal macrophages play a key
role in the maintenance of mucosal homeostasis and progression of
tissue destructive immune responses. In the normal intestine,
macrophages express low levels of microbe-associated molecular
pattern receptors, including the lipopolysaccharide (LPS) recep-
tors, CD14 and toll-like receptor (TLR)-4, produce anti-inflam-
matory molecules [e.g. (interleukin)-10, IL-25] and are able to
engulf and kill microbes without eliciting inflammatory responses
[3,4,5]. In contrast, during chronic inflammatory disorders, such
as Crohn’s disease (CD) and Ulcerative colitis (UC), the major
forms of inflammatory bowel disease (IBD) in human beings,
macrophages express high levels of CD14, TLRs and co-
stimulatory molecules and synthesize huge amounts of pro-
inflammatory mediators in response to bacterial stimulation
[2,6]. Phenotypic analysis of surface-cell markers has contributed
to show that distinct macrophage subsets infiltrate the gut of
patients with CD and patients with UC, even though the role that
each macrophage subpopulation plays in the pathogenesis of IBD
is not fully understood [7,8].
The plasma membrane glycoprotein CD163, a member of the
scavenger receptor cystein-rich (SRCR) superfamily class B, is
highly expressed on resident tissue macrophages and to lesser
extent on monocytes [9]. Initial studies identified CD163 as a
scavenger receptor for hemoglobin (Hb)-haptoglobin (Hp) com-
plexes formed during intravascular hemolysis [10]. More recently
it has been demonstrated that CD163 can bind additional ligands,
such as the tumor necrosis factor (TNF)-a-like weak inducer of the
apoptosis protein, some bacteria and virus and either inhibit or
amplify inflammatory responses depending on the context
analyzed [11]. For example, in monocyte-derived macrophages
treated with glucocorticoid, cross-linking of CD163 with EDHU1-
Ab, a specific monoclonal anti-CD163 antibody direct against the
SRCR3 domain of CD163, induces a protein tyrosine kinase- and
casein kinase II-dependent signal that leads to calcium mobiliza-
tion, inositol triphosphate production and secretion of pro-
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inflammatory cytokines (i.e. TNF-a, IL–1b and IL-6) [12,13].
CD163 can also facilitate Gram-positive and -negative bacteria-
induced proinflammatory cytokine response [14]. Consistently,
up-regulation of CD163 has been documented in many inflam-
matory pathologies [15,16,17,18]. On the other hand, there is
evidence that CD163-expressing macrophages produce counter-
regulatory molecules, which are involved in the resolution of many
inflammatory processes [19]. In addition to the full-length moiety,
a soluble form of CD163 (sCD163), generated by shedding of the
cell-surface protein by matrix metalloproteinases, [20,21] is
elevated in many inflammatory conditions. sCD163 inhibits
activation of human T lymphocytes thereby contributing to
suppression of inflammatory responses [22].
Previous studies have evaluated CD163 in IBD with conflicting
results [23,24,25] probably depending on the methodology
adopted to assess the expression of the scavenger. Our study was
aimed at further characterizing the tissue distribution of CD163 in
IBD and ascertaining whether CD163-delivered signals are either
inflammatory or anti-inflammatory in the gut. Using several
techniques, we here show that: CD163-expressing cells are
abundant in the inflamed intestine of patients with CD and
patients with UC; IL-6, a cytokine over-produced in IBD,
positively regulates CD163 expression in normal lamina propria
mononuclear cells (LPMC) and mucosal explants; CD163 triggers
inflammatory signals. Overall these data suggest a novel mecha-
nism by which mucosal inflammation is amplified and perpetuated
in IBD.
Materials and Methods
Ethics Statement
Each patient who took part in the study gave written informed
consent and the study protocol was approved by the local Ethics
Committees (Tor Vergata University Hospital, Rome).
Patients and samples
Biopsies were taken from the inflamed mucosa of 12 patients
with colonic CD, 7 patients with ileocolonic CD, 1 patient with
ileal CD and 25 patients with UC undergoing colonoscopy for a
clinically active disease at the Gastrointestinal Unit of Tor Vergata
University (Rome, Italy) or Fondazione IRCCS Ca` Granda,
Ospedale Maggiore Policlinico (Milan, Italy). Paired biopsies were
also taken from the inflamed and uninflamed mucosa of 3 patients
with ileocolonic CD and 6 patients with UC. Eleven patients (2
colonic CD, 2 ileocolonic CD and 7 UC) were taking no drug and
biopsies were collected at the time of initial diagnosis. Moreover,
biopsies were taken from 18 patients (7 colonic CD, 2 ileocolic
CD, and 9 UC) receiving mesalamine, 10 patients (1 colonic CD, 2
ileocolonic CD, and 7 UC) taking steroids and 6 patients (2 colonic
CD, 1 ileocolonic CD, 1 ileal CD and 2 UC) on immunosup-
pressive drugs. In all these patients, endoscopy was performed for
a clinical relapse of the disease.
Additionally, surgical specimens were taken from 15 patients
with colonic CD and 19 patients with UC undergoing surgery for
a chronic active disease poorly responsive to medical treatment
and from 10 patients with ileal CD undergoing surgery due to
stricturing disease. In 3 out of 19 UC patients, surgical specimens
were available from both involved and uninvolved mucosa.
Clinical characteristic of IBD patients are shown in table 1.
Controls (CTR) included biopsies taken from unaffected colonic
mucosa of 22 subjects and unaffected ileal mucosa of 7 subjects
undergoing colonoscopy for colorectal cancer screening. Addi-
tional controls were mucosal specimens taken from macroscopi-
cally and microscopically unaffected colonic areas of 24 patients
undergoing surgery for colon cancer.
Autologous peripheral blood samples were obtained by standard
venipucture from 9 UC patients, 27 CD patients and 9 CTR.
RNA extraction, cDNA preparation and real-time PCR
Total RNA was extracted using TRIzol reagent (Invitrogen,
Milan, Italy). A constant amount of RNA (1 mg/sample) was retro-
transcribed into complementary DNA (cDNA) and then 1 ml of
cDNA/sample was amplified using the following conditions:
denaturation 1 minute at 95uC; annealing 30 seconds at 62uC
for TNF-a and at 60uC for b-Actin, followed by 30 seconds of
extension at 72uC. Primers sequence was as follows: TNF-a:
forward, 59-AGGCGGTGCTTGTTCCTCAG-39; reverse, 59-
GGCTACAGGCTTGTCACTCG -39; b-actin: forward, 59-
AAGATGACCCAGATCATGTTTGAGACC-39; reverse, 59-
AGCCAGTCCAGACGCAGGAT-39) was used as internal con-
trol gene.
CD163 was evaluated using a commercial TaqMan probe
(Applied Biosystems, Foster City, CA). RNA expression was
calculated relative to the housekeeping b-Actin gene on the base of
the DDCt algorithm.
Total protein extraction and Western blotting
Colonic mucosal explants of CTR, UC patients and CD
patients were lysed on ice in buffer containing 10 mM HEPES
(pH 7.9), 10 mM KCl, 0.1 mM EDTA, 0.2 mM EGTA and 0.5%
Nonidet P40 supplemented with 1 mM dithiothreitol, 10 mg/ml
aprotinin, 10 mg/ml leupeptin, 1 mM phenylmethylsulfonyl
fluoride, 1 mM Na3VO4 and 1 mM NaF. Lysates were clarified
Table 1. Clinical characteristic of Crohn’s disease patients and
ulcerative colitis patients.
CD n=72 UC n=53
Gender, male: n (%) 38 (52.7) 28 (52.8)
Age: median (range) 33 (22–65) 50 (20–82)
CD location: n (%)
Terminal ileum 24 (33.3)
Pre-anastomotic ileum 5 (6.9)
Ileo-colon 13 (18.1)
Colon 30 (41.7)
UC extent: n (%)
Proctitis 7 (13.3)
Left-side colitis 19 (35.8)
Extensive colitis 27 (50.9)
Current therapy: n (%)
None 4 (5.5) 7 (13.3)
Sistemic CS 32 (44.4) 29 (54.7)
Budesonide 3 (4.2)
Mesalamine 21 (29.2) 11 (20.7)
ISS 8 (11.1) 3 (5.6)
Anti-TNF 2 (2.8) 1 (1.9)
Sistemic CS+ISS 2 (2.8) 1 (1.9)
Sistemic CS+Anti-TNF 1 (1.9)
Abbreviations: CD, Crohn’s disease, UC, ulcerative colitis, CS, corticosteroids, ISS,
immunosuppressive drugs, TNF, tumor necrosis factor.
doi:10.1371/journal.pone.0069839.t001
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by centrifugation at 4uC, 12.0006g for 30 minutes, and separated
on 8% sodium dodecyl sulphate-poliacrilamide gel electrophoresis.
CD163 was detected using a mouse anti-human CD163 (AbD
Serotec Endeavour House, Langford Lane, Kidlington, UK)
followed by a horseradish peroxidase–conjugated rabbit anti-
mouse IgG monoclonal antibody (Dako, Milan, Italy). The
reaction was detected with a sensitive enhanced chemilumines-
cence kit (Pierce, Rockford, IL). After the analysis of CD163, blots
were stripped and incubated with a mouse anti-human b-Actin
antibody (Sigma-Aldrich, Milan, Italy) as internal loading control,
followed by a goat anti-mouse antibody conjugated to horseradish
peroxidase.
Immunohistochemistry
Immunohistochemistry was performed on formalin-fixed, par-
affin-embedded sections of CTR and IBD patients. The sections
were deparaffinized and dehydrated through xylene and ethanol
and the antigen retrieval was performed in citrate buffer (pH 6.0)
for 20 minutes in microwave. Immunohistochemical staining was
performed using a mouse monoclonal antibody directed against
human CD163 (Biocare Medical, Concord, CA) or human CD68
(Dako) at room temperature for 1 hour followed by a biotin-free
HRP-polymer detection technology with 3,39diaminobenzidine
(DAB) as a chromogen (MACH 4 Universal HRP-Polymer Kit,
Biocare Medical). The sections were counterstained with haema-
toxylin, dehydrated and mounted. Isotype control IgG-stained
sections were prepared under identical immunohistochemical
conditions as described above, replacing the primary antibody
with a purified mouse normal IgG control antibody (R&D
Systems, Minneapolis, MN, USA). The CD163- and CD68-
expressing cells were counted in at least 3 fields per section using
IAS 2000 System (Delta Sistemi, Rome, Italy) and expressed as
number of cells for high power field (hpf).
Ex vivo organ cultures
Freshly obtained normal colonic mucosal samples were cultured
as described elsewhere [26]. Briefly, samples were placed on iron
grids with the mucosal face upward in the central well of an organ
culture dish containing AQIX medium (Aqix Ltd, London, UK)
supplemented with 1% L-glutamine penicillin (P) (100 U/ml),
streptomycin (S) (100 mg/ml) and gentamycin (G) (50 mg/ml) (all
from Lonza Vervies, Belgium) in the presence or absence of TNF-
a (20 ng/ml, R&D Systems) or IL-6 (50 ng/ml, R&D Systems).
Dishes were then placed in a tight container with 95% O2, and
5% CO2 at 37uC, at 1 bar. After 24 hours, mucosal samples were
used to evaluate CD163 expression by Western blotting.
Cell Isolation, Purification of HLA-DR-expressing LPMC
and Culture
Human peripheral blood mononuclear cells (PBMC) were
isolated from EDTA-stabilized blood samples of CTR and IBD
patients by Ficoll gradients and used for flow cytometry analysis or
to perform cell cultures in RPMI 1640 medium supplemented with
10% fetal bovine serum (FBS) and P/S/G.
LPMC were isolated from colonic specimens of CTR and IBD
patients as described elsewhere [27] and resuspended in RPMI
1640 medium supplemented with 10% FBS and P/S/G.
Moreover, LPMC isolated from surgical specimens of CTR and
CD patients were depleted of CD3- e CD19-positive cells and then
used to purify HLA-DRII-expressing cells by commercial kits
(Miltenyi Biotec, Bergish Gladbach, Germany) according to the
manufacturer’s instruction. To evaluate whether inflammatory
stimuli can modulate CD163 expression, normal LPMC (or HLD-
DR-expressing LPMC) were seeded at a concentration of 26106
cells/ml into 24-well culture dishes either left unstimulated or
stimulated with TNF-a 20 ng/ml, R&D Systems) or IL-6 (50 ng/
ml, R&D Systems) for 48 hours and then analyzed by Western
blotting. To examine functional properties of CD163, IBD LPMC
Figure 1. CD163 transcripts are increased in inflamed IBDmucosa. A. CD163 RNA expression was evaluated in colonic biopsies taken from 22
normal controls (CTR), 25 patients with Ulcerative Colitis (UC) and 19 patients with Crohn’s disease (CD) by real-time PCR and levels were normalized
to b-actin. Data indicate mean6 SEM of all samples; *p = 0.01; **p,0.0001. B. CD163 RNA expression was evaluated in ileal biopsies taken from 7 ileal
CTR and 6 ileal CD patients by real-time PCR. Data indicate mean 6 SEM of all samples; *p = 0.03. C. Colonic biopsies taken from 22 CTR, 11 IBD
patients (4 CD and 7 UC) receiving no therapy (w/o therapy), 18 IBD patients (9 CD and 9 UC) treated with mesalamine (5-ASA), 10 IBD patients (3 CD
and 7 UC) treated with steroids (CS) and 5 IBD patients (3 CD and 2 UC) treated with immunomodulators (ISS) were analyzed for CD163 RNA
expression by real-Time PCR. Levels are normalized to b-actin. Data are expressed as mean 6 SEM of all samples; *p = 0.01; **p,0.01. D. CD163 RNA
expression was evaluated in LPMC from 6 normal controls (CTR), 4 patients with UC and 6 patients with CD by real-time PCR. Levels are normalized to
b-actin. Data indicate mean 6 SEM of all samples; *p = 0.02.
doi:10.1371/journal.pone.0069839.g001
CD163-Positive Cells in IBD
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(or IBD HLA-DR-expressing LPMC) and PBMC were seeded at a
concentration of 16106 cells/ml into 48-well culture dishes pre-
coated with 10 mg/ml EDHU1-Ab (AbD Serotec, Du¨sseldorf,
Germany) or control Ab mouse IgG1 (R&D Systems) for 2 hours
at 37uC and cultured for 6 and 48 hours. To examine whether
CD163 expression correlates with TNF-a production, PBMC
were isolated from IBD patients and used to purify CD14+
monocytes using isolation kit (Miltenyi Biotec, Bergish Gladbach,
Germany) according to the manufacturer’s instruction. RNA was
then extracted from those cell samples and CD163 and TNF-a
RNA transcripts were evaluated by Real Time PCR.
TNF-a enzyme-linked immunosorbent assay
TNF-a was measured in supernatants of IBD LPMC and
PBMC cultured for 48 hours as described above using a sensitive
commercial enzyme-linked immunosorbent assay (ELISA) kit
(R&D Systems) according to the manufacturer’s instructions.
Figure 2. CD163 protein expression is increased in IBD. A. Representative Western blots showing CD163 and b actin in total proteins extracted
from mucosal samples of 2 CTR, 2 UC patients and 2 CD patients. Right panel shows the quantitative analysis of CD163/b-actin ratio in mucosal
samples taken from 8 CTR, 8 UC patients and 8 CD patients as measured by densitometry scanning of Western blots. Values are expressed in arbitrary
units (a.u.) and indicate mean 6 SEM of all samples; *p = 0.003; **p= 0.03. B. Representative photomicrographs (1006 original magnification) of
CD163-stained paraffin-embedded sections of surgical samples taken from 1 CTR, 1 patient with UC and 1 patient with CD. Isotype control antibody-
stained section is also shown. Right panel shows the number of CD163-positive cells for high power field (hpf) in colonic sections taken from 3 CTR, 3
UC patients and 4 CD patients. Data are expressed as mean 6 SD; *p = 0.03; **p= 0.02. C Representative photomicrographs (2006 original
magnification) of CD163-stained paraffin-embedded sections of surgical samples taken from 1 patient with UC and 1 patient with CD. CD163-positive
cells are evident inside and around vessels. Insets show higher magnification (4006) images.
doi:10.1371/journal.pone.0069839.g002
Figure 3. CD163 RNA and protein expression is increased in the inflamed areas of IBD. A. Paired biopsies taken from the involved (Involv)
and uninvolved (Uninv) mucosa of 6 UC patients and 3 CD patients were analyzed for CD163 RNA expression by real-time PCR. Levels are normalized
to b-actin; horizontal bars indicate the median values; *p = 0.003. B. Representative photomicrographs (original magnification 1006) of CD163-stained
sections of colonic mucosal samples taken from involved and uninvolved mucosa of 1 UC patient. Right panel shows the number of CD163-positive
cells per high power field (hpf) of colonic sections taken from the involved (Involv) and uninvolved (Uninv) mucosa of 3 UC patients. Data indicate the
mean values 6 SEM of all samples; **p = 0.01.
doi:10.1371/journal.pone.0069839.g003
CD163-Positive Cells in IBD
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Flow cytometry analysis
CTR and IBD PBMC were stained with CD163 PE (1:50 final
dilution; eBioscience, San Diego, CA), CD14 FITC, (1:50 final
dilution, Immunotools, Friesoythe; Germany), CD16 PerCP (1:50
final dilution; Invitrogen) or isotype control IgGs (BD Biosciences)
and cell-surface fluorescence intensity was assessed using a
FACSCalibur analyzer and analyzed using CellQuest software
(BD Biosciences, Milan, Italy).
Statistical analysis
Differences between groups were compared using the Mann–
Whitney U test and Wilcoxon test. Correlation between CD163
and TNF-a was examined using Spearman’s non parametric
correlation.
Results
CD163 RNA transcripts are up-regulated in IBD
CD163 RNA expression was more pronounced in both CD and
UC colonic samples in comparison to CTR (Fig. 1A). UC biopsies
contained more CD163 transcripts than CD biopsies but the
difference was not statistically significant (Fig. 1A). High CD163
RNA was also seen in ileal CD samples as compared to ileal CTR
samples (Fig. 1B). To exclude the possibility that up-regulation of
CD163 in IBD was secondary to current therapy, CD163 RNA
transcripts were compared between patients receiving or not
drugs. Figure 1C shows that CD163 RNA expression was not
influenced by the ongoing treatments. Finally, we showed that
CD163 transcripts were up-regulated in IBD LPMC as compared
to control samples (Fig. 1D).
Figure 4. Increased CD163+cells/CD68+ cells ratio in IBD tissue. A. Representative photomicrographs (1006original magnification) in serial
paraffin-embedded sections of surgical samples taken from 1 CTR, 1 patient with UC and 1 patient with CD and stained with CD163 or CD68. Right
panel shows the ratio of CD163+ and CD68+ cells counted in colonic sections taken from 3 CTR, 3 UC patients and 3 CD patients. Horizontal bars
indicate the median values; *p = 0.03; **p= 0.02.
doi:10.1371/journal.pone.0069839.g004
CD163-Positive Cells in IBD
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CD163-positive cells accumulate in the inflamed intestine
of IBD patients
Western blotting analysis showed that CD163 was expressed in
all IBD and CTR samples, but immunoreactivity corresponding to
CD163 was more pronounced in IBD in comparison to CTR
(Fig. 2A). Immunohistochemical analysis confirmed the abundant
expression of CD163 in IBD and showed accumulation of these
cells around the deep ulcers (Fig. 2B, right lower panel) and
around and inside the blood vessels (Fig. 2C).
To examine whether, in IBD, CD163 is restricted to areas with
mucosal lesions, paired biopsies were taken from both involved
and uninvolved areas of IBD patients and examined for CD163 by
real-time PCR and immunohistochemistry. CD163 RNA and
protein expression was up-regulated in the inflamed samples as
compared to uninvolved mucosal samples of the same IBD
patients (Fig. 3). In contrast, expression of CD163 did not differ
between uninvolved biopsies of IBD patients and normal CTR
(not shown). Moreover, serial sections of IBD and control
specimens stained with CD163 or CD68 showed that the number
of CD68-expressing cells was higher than that of CD163-positive
cells in control samples, while in both CD and UC the number of
CD163-positive cells exceeded that of CD68-expressing macro-
phages (Fig. 4). These data suggest that up-regulation of CD163
cells in IBD mucosa is not secondary to the increased macrophage
infiltration.
CD163 -positive PBMC are increased in IBD
The fact that, in IBD tissue, CD163-expressing cells are located
around and inside blood vessels (Fig. 2B–C) raises the possibility
that these cells are in part recruited from the systemic circulation.
Thus, in subsequent experiments, we evaluated the expression of
CD163 in PBMC of IBD patients and CTR. The percentage of
CD163-expressing PBMC was increased in IBD patients as
compared to CTR (Fig. 5A). Further analysis revealed that the
fractions of CD14+, CD16+ and CD14+/CD16+ cells expressing
CD163 were increased in IBD PBMC in comparison to control
PBMC (Fig. 5 B–D).
IL-6 enhances CD163 expression in normal colonic
explants and LPMC
Next, we determined whether CD163 can be modulated by
cytokines over-produced in IBD [28,29]. To this end, normal
colonic explants and LPMC were stimulated with TNF-a and IL-
6, two cytokines that up-regulate CD163 in other systems [28,29].
Western blot analysis showed that IL-6, but not by TNF-a
increased CD163 protein expression in both explants and LPMC
(Fig. 6A–B). To examine whether increased expression of CD163
resulted from direct effects of IL-6 on normal intestinal
macrophages, HLA-DR-expressing CD3- and CD19-negative
LPMC were stimulated with IL-6 for 6 hours and then CD163
RNA was evaluated by real-time PCR. IL-6 enhanced CD163
RNA transcripts in all samples analyzed (1.260.2 in unstimulated
cells vs 561.4 in IL-6-stimulated cells).
Cross-linking of CD163 with EDHU1-Ab increases TNF-a
production
In a final set of experiments we evaluated if CD163-delivered
signals control cytokine expression. IBD LPMC and PBMC were
cultured in the presence or absence of a specific activating CD163
monoclonal antibody (EDHU1-Ab) or control IgG for 6–48 hours
and TNF-a RNA and protein were then examined by real-time
PCR and ELISA respectively. Cross-linking of CD163 with
EDHU1-Ab increased TNF-a RNA and protein expression and
this was evident in both LPMC and PBMC (Fig. 7A–B).
Consistently, stimulation of CD HLA-DR-expressing CD3- and
CD19-negative LPMC with EDHU1-Ab increased TNF-a RNA
expression (Fig. 7C). Although these data indicate that CD163
cross-linking on monocytes/macrophages enhances TNF-a ex-
pression, no correlation was seen between CD163 and TNF-a
transcripts in CD14+ monocytes isolated from blood of IBD
patients (not shown), perhaps due to the multiple signals
controlling TNF-a production in monocytes/macrophages.
Discussion
The present study was undertaken to evaluate the expression
and function of CD163 in IBD. CD163 is a multifunctional
receptor, which can bind multiple ligands and activate various
Figure 5. CD163-expressing cells are increased in the blood of IBD patients. A. The Histograms show the percentage of CD163-expressing
cells in total PBMC (A), CD14+ cells (B), CD16+ cells (C) and CD14+ CD16+ cells (D) of 23 IBD patients (5 UC patients, 18 CD patients) and 9 CTR. Cells
were isolated from the blood of IBD patients and controls and examined by flow-cytometry as indicated in material and methods. Data indicate the
mean values 6 SEM of all samples; *p,0.001 **p= 0.001.
doi:10.1371/journal.pone.0069839.g005
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intracellular pathways, thereby controlling many biological
processes. Initial studies showed that CD163 identifies a specific
subsets of alternatively activated macrophages [30], which exert
anti-inflammatory effects following interaction and internalization
of the complex Hb-Hp [10]. This function of CD163 was
supported by the demonstration that CD163-expressing macro-
phages constitute the predominant macrophage population during
the late or resolution phase of many inflammatory reactions
[31,32] and CD163 expression is strongly induced by anti-
inflammatory mediators, such as glucocorticoids and IL-10
[33,34]. More recently, it has been demonstrated that CD163
can also bind both Gram-negative and Gram-positive bacteria and
activate a number of intracellular events, which lead to production
of pro-inflammatory cytokines [14]. Therefore, it is plausible that
CD163 may have a dual role in the control of immune responses
perhaps depending on the microenvironment in which CD163-
expressing cells are located.
We here show that IBD-related inflammation is marked by
enhanced CD163 expression at both RNA and protein level. High
CD163 is restricted to mucosal areas with active inflammation and
not influenced by current therapy. While this study was ongoing,
Bain and co-workers showed that CD14-positive LPMC isolated
from the inflamed ileum of CD patients express low levels of
CD163 as compared to control cells [25]. We have attempted to
reproduce such results using the same LPMC isolation and flow-
cytometry procedures adopted by Bain. However, CD163 was
undetectable on LPMC of both IBD patients and controls using 3
different commercial flow-cytometry antibodies, including that
used by Bain and co-workers. The reason for this apparent
discrepancy remains unknown. The fact that analysis of this
receptor in our samples was performed using a very sensitive
technique (i.e. real-time PCR) and data were confirmed by
Western blotting and immunohistochemistry suggests however
that CD163 is over-expressed in the inflamed mucosa of IBD
patients. This hypothesis is supported by a previous immunostain-
ing study showing enhanced accumulation of CD163+ macro-
phages in the intestinal mucosa of patients with CD and patients
with spondyloarthropathy [23]. CD163 was detectable in PBMC
by flow-cytometry and positivity was not affected by exposure of
cells to reagents used to isolate LPMC (e.g. EDTA, collagenase).
Thus, it is unlikely the difficulty to detect CD163 in LPMC by
flow-cytometry is secondary to cleavage of the receptor during the
cell preparations.
The relevance of the increased number of CD163+ cells in IBD
tissue is highlighted by further observations. First, the increase of
CD163+ cells reflects an increase of a specific macrophage
subpopulation rather than a global increase of macrophages, since
the number of CD68+ cells was similar or even decreased to that
of CD163+ cells in IBD samples. Second, the up-regulation of
CD163+ cells in patients with CD and patients with UC could
reflect a similar pathophysiological mechanism, which accounts for
the accumulation of this particular cell subset in the two IBD.
Third, CD163 was enhanced in normal LPMC by IL-6, a cytokine
that is over-produced in both CD and UC and supposed play a
key role in the pathogenesis of IBD-associated tissue-damaging
immune response. Fourth, cross-linking of CD163 with a specific
activating antibody leads to enhanced production of TNF-a in
cultures of IBD LPMC and HLADR-expressing LPMC.
Overall our data are in line with previous studies documenting
high expression of CD163 in pathological conditions. For
example, Yawalkar and Fuentes-Duculan demonstrated that
CD163-positive macrophages infiltrate heavily the lesional skin
of psoriatic patients and express bioactive forms of pro-inflamma-
tory cytokines, such IL-12 and IL-23 [15,16]. Consistent with this
is the demonstration that CD163-positive macrophages infiltrating
the fibrous tissue in facet joints of patients with ankylosing
spondylitis are a major source of inflammatory cytokines, such IL-
23 [35]. Wakusawa et al described a patient with Necrobiosis
lipoidica associated with Insulin-dependent type 1 diabetes
mellitus, in which granulomas contained mostly pro-inflammatory
CD163-positive macrophages [36]. Increased expression of
CD163 has been also seen in skin macrophages and peripheral
blood monocytes of patients with systemic sclerosis, an autoim-
mune disease characterized by local inflammatory infiltrates and
widespread fibrosis [37]. CD163-expressing macrophages are also
overrepresented in the colon of patients with diverticulitis [38] and
in the kidney of patients with IgA nephropathy [39].
In conclusion, data of the present study show that CD163+ cells
are abundant in the inflamed gut of patients with IBD and suggest
a role for these cells in the amplification and perpetuation of the
ongoing mucosal inflammation in IBD.
Figure 6. IL-6 enhances CD163 expressions in normal colonic
explants and LPMC. A. Representative Western blots showing CD163
and b-actin in total proteins extracted from normal colonic explants
treated with or without (unstimulated=UNST) TNF-a (20 ng/ml) or IL-6
(50 ng/ml) for 24 hours. Right panel shows the quantitative analysis of
CD163/b-actin ratio in normal colonic explants. Values are expressed in
arbitrary units (a.u.) and indicate mean 6 SEM of four separate
experiments; *p = 0.04. B. Representative Western blots showing CD163
and b-actin in total proteins extracted from normal LPMC treated as
above for 48 hours. Right panel shows the quantitative analysis of
CD163/b-actin ratio in LPMC protein extracts. Values are expressed in
arbitrary units (a.u.) and indicate mean 6 SEM of three separate
experiments; **p = 0.01.
doi:10.1371/journal.pone.0069839.g006
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